BiomX Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHGE research report →
Companywww.biomx.com
BiomX Inc. , a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).
- CEO
- Michael Oster
- IPO
- 2019
- Employees
- 52
- HQ
- Ness Ziona, IL
Price Chart
Valuation
- Market Cap
- $951.20K
- P/E
- -165.34
- P/S
- 0.00
- P/B
- -1764.15
- EV/EBITDA
- 0.01
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -136.91%
- ROIC
- -2881.09%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-36,199,000 · -104.20%
- EPS
- $-22.19 · 20.55%
- Op Income
- $-32,909,999
- FCF YoY
- 28.69%
Performance & Tape
- 52W High
- $14.71
- 52W Low
- $0.36
- 50D MA
- $2.69
- 200D MA
- $5.88
- Beta
- 1.03
- Avg Volume
- 240.52K
Get TickerSpark's AI analysis on PHGE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 16, 26 | Yeganeh Reuven | sell | 1,300,000 |
| Mar 16, 26 | Yeganeh Reuven | sell | 2,000,000 |
| Mar 17, 26 | Yeganeh Reuven | other | 530,000 |
| Mar 16, 26 | Yeganeh Reuven | other | 450,000 |
| Mar 16, 26 | Yeganeh Reuven | other | 900 |
| Mar 17, 26 | Yeganeh Reuven | other | 1,060 |
| Mar 17, 26 | Yeganeh Reuven | sell | 530,000 |
| Mar 16, 26 | Yeganeh Reuven | sell | 1,700,000 |
| Mar 13, 26 | Yeganeh Reuven | other | 370,000 |
| Mar 11, 26 | Yeganeh Reuven | other | 300,000 |
Our PHGE Coverage
We haven't published any research on PHGE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PHGE Report →